Quaker Chemical Q2 sales beat estimates

Quaker Chemical

31/07/2025 21:44

Overview

Quaker Chemical Q2 sales rise 4% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 misses consensus, impacted by impairment charge

Co repurchased $32.7 mln in shares in Q2, raised dividend by 5%

Outlook

Company expects full-year 2025 revenue and earnings similar to 2024

Quaker Chemical anticipates $20 mln cost savings by end of 2026

Company sees economic conditions remaining challenging in H2 2025

Quaker Chemical plans to leverage strong balance sheet for shareholder value

Result Drivers

SALES GROWTH - Driven by 2% increase in organic volumes and 6% contribution from acquisitions, partially offset by 4% decline in selling price and product mix

ASIA/PACIFIC PERFORMANCE - 8% organic volume growth in Asia/Pacific segment, offsetting soft market conditions in Americas and EMEA

IMPAIRMENT CHARGE - $88.8 mln non-cash goodwill impairment in EMEA segment contributed to net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$483.40 mln
$461.10 mln (4 Analysts)
Q2 Adjusted EPS
Miss
$1.71
$1.83 (5 Analysts)
Q2 Adjusted Net Income
$30 mln
Q2 Net Income
-$66.58 mln
Q2 Adjusted EBITDA
$75.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the commodity chemicals peer group is "buy"

Wall Street's median 12-month price target for Quaker Chemical Corp is $150.00, about 23.5% above its July 30 closing price of $114.71

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn1FcN7Na

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)